Roche Diagnostic Gene Mutation Detection Guides Cancer Targeted Therapy
Release date: 2014-12-01
Roche Diagnostics announced that its cobas KRAS gene mutation detection has been approved by the China Food and Drug Administration. By accurately identifying the KRAS gene mutation status, it can help doctors select a treatment plan suitable for the patient's genetic traits and promote individualized medicine.
Lung cancer is most common in non-small cell lung cancer (NSCLC), including adenocarcinoma and squamous cell carcinoma. EGFR is the main driving gene of East Asian adenocarcinoma. International clinical studies show that tyrosinase inhibitor (TKI)-targeted drugs are more effective than chemotherapy for NSCLC patients with EGFR gene mutation. Is EGFR gene mutation a patient? Targeted therapy-sensitive strong predictors, EGFR testing before treatment can help guide clinical personalized medication.
"Because lung cancer has different histological types and stages, the treatment options are different, and it is necessary to advocate comprehensive treatment of multidisciplinary cooperation." Professor Wang Dong, Dean of the Daping Hospital Cancer Specialist Hospital of the Third Military Medical University pointed out that the clinical stage of advanced NSCLC Treatment has selected a treatment regimen based on patient-based clinicopathological features to translate into gene-targeted therapies based on molecular expression profiles of patient tumors.
Anti-EGFR treatment for advanced colorectal cancer can only be effective for KRAS wild-type patients. KRAS detection before treatment can clearly distinguish the gene mutation status of patients and guide individualized targeted therapy. The European Society of Clinical Oncology and the American Society of Clinical Oncology recommend the detection of EGFR gene mutations in patients with advanced NSCLC, and recommend KRAS gene mutation detection to select colorectal patients.
"According to epidemiological investigations, the incidence of colorectal cancer is rising, and young people are gradually increasing." Professor Wang Dong said that with the advent of targeted therapeutics, colorectal cancer has entered the era of targeted drug therapy. Anti-VEGF antibody, anti-EGFR antibody combined with chemotherapy combined with targeted drugs can bring more clinical benefits, and has become one of the main ways of clinical cancer treatment, which can significantly prolong the survival of patients with metastatic colorectal cancer.
Professor Du Xiang, director of the Department of Pathology, Fudan University Cancer Hospital, stressed the significance of cobas KRAS gene mutation detection, stressed that non-standard detection methods will lead to partial KRAS mutation patients receiving false anti-EGFR inhibitor treatment, not only the treatment effect is not Good, also greatly waste the patient's limited treatment window and economic strength. At the same time, the approved Roche diagnostic cobas KRAS gene mutation detection is based on a stable and advanced PCR platform, and the automatic interpretation program ensures the accuracy and consistency of pathological diagnosis results to the greatest extent.
Source: China Science and Technology Network
Gaffer tape introduction
1. Material
Our gaffer tape is based on premium grade cloth fabric, combined with matt polyethylene, coated with synthetic rubber adhesive or natural rubber adhesive.
2. Features
Our Gaffer tape has following features:
a. Strong adhesion, we coated with high quality imported glue.
b. Heavy duty, it is made from strong material, thickness reaches 250micron, 270micron and 300micron.
c. Matt surface, non reflective.
d. No residue when removal.
e. Different colors for choosing. We have black, orange, pink, apple green, other colors also can be customized.
Gaffer Tape,Cloth Gaffer tape,Gaffers Tape,Gaff Tape,Black Gaffer tape,Gaffer duct tape
Kunshan Jieyudeng Intelligent Technology Co., Ltd. , https://www.yuhuanptapes.com